Human Non Small Cell Lung Cancer FFPE Sections

Non-small cell lung cancer (NSCLC) is a type of lung cancer that differs from small cell lung cancer (SCLC) in terms of its histological features and behavior. NSCLC accounts for the majority of lung cancer cases, representing about 85-90% of all diagnosed lung cancers.
There are several subtypes of non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype has distinct characteristics based on the type of cells involved and their appearance under a microscope:
Adenocarcinoma: This is the most common subtype of NSCLC. It often arises in the outer regions of the lungs and is more frequently found in non-smokers and former smokers. Adenocarcinoma can occur in both peripheral and central areas of the lung.
Squamous Cell Carcinoma: This subtype usually develops in the lining of the bronchial tubes. It is often linked to a history of smoking and is more likely to be found centrally in the lungs.
Large Cell Carcinoma: This is a less common subtype and is characterized by large, abnormal-looking cells. Large cell carcinoma can occur in any part of the lung and tends to grow and spread quickly.
Unlike SCLC, NSCLC tends to grow more slowly, and it is often diagnosed at a later stage. Treatment options for non-small cell lung cancer depend on various factors, including the stage of the cancer, the specific subtype, and the overall health of the patient. Treatment modalities may include surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy. Early detection through screenings and prompt medical attention are crucial for improving the chances of successful treatment outcomes.
VitroVivo Biotech provide high quality NSCLC FFEP setions for research. These FFPE slides can be used to perform RNA scope in situ hybridization (ISH), fluorescence in situ hybridization (FISH), Immunofluorescence(IF), immunohistochemistry (IHC) and next-generation sequencing (NGS), etc.

SKU#	Sex	Age	Pathology DX	TNM	Stage	Grade	Tested Biomarkers
HuPS-03001T	Female	73	Adenocarcinoma	N/A	N/A	2	CK7 (+), EGFR(+), TTF-1 (+), Ki 67 (+, 60%)
HuPS-03002T	Male	70	Adenocarcinoma	N/A	N/A	2
HuPS-03003T	Male	51	Adenocarcinoma	N/A	N/A	2	CK (+), SP-A (+), TTF-1 (+), P40 (+), CK5/6 (-)Ki 67 (+, 15%)
HuPS-03004T	Male	57	Adenocarcinoma	N/A	N/A	3	CK(+), CK7 (+), CK20(-), TTF-1 (+)
HuPS-03005T	Male	57	Squamous cell  carcinoma	N/A	N/A	2	CK(+), P63(+), CK5/6(+), TTF-1 (-), Napsin A (-),CD56 (-)
HuPS-03006T	Male	53	Adenocarcinoma	N/A	N/A	2	CK7 (+), CK20 (-), CK5/6(-), P63 (-),TTF-1 (+), Napsin A(-),Ki 67 (+, 35%)
HuPS-03007T	Male	66	Adenocarcinoma	T2aN2M0	IIA	2
HuPS-03008T	Male	55	Adenocarcinoma	T1cN0M0	IA	2
HuPS-03009T	Male	67	Squamous cell  carcinoma	T3N0M0	IIB	2
HuPS-03010T	Male	58	Adenocarcinoma	T1cN2M0	IIIA	2
HuPS-03011T	Male	74	Adenocarcinoma	T1cN0M0	IA	2
HuPS-03012T	Male	59	Adenocarcinoma	T1cN0M0	IA	3
HuPS-03013T	Male	73	Squamous cell  carcinoma	T2bN1M0	IIB	2
HuPS-03014T	Male	63	Squamous cell  carcinoma	T2bN1M0	IIB	2
HuPS-03015T	Female	70	Adenocarcinoma	T4N2Mia	IV	3
HuPS-03016T	Female	73	Adenocarcinoma	T2bN1Mo	IIB	2
HuPS-03017T	Female	59	Adenocarcinoma	T2aN1Mo	IIB	2
HuPS-03018T	Male	67	Squamous cell  carcinoma	T2aN0M0	IIA	2
HuPS-03019T	Male	71	Adenocarcinoma	T2aN0M0	IIA	2	EML4-ALK(p23,q21) fusion+
HuPS-03020T	Male	49	Adenocarcinoma	T2aN0M0	IIA	2	EML4-ALK(p23,q21) fusion+
HuPS-03021T	Male	49	Adenocarcinoma	T3N1M0	IIIA	3	EML4-ALK(p23,q21) fusion+
HuPS-03022T	Male	64	Adenocarcinoma	T3N2M0	IIIb	2	EML4-ALK(p23,q21) fusion+
HuPS-03023T	Male	63	Adenocarcinoma	T4N1M0	IIIA	2	EML4-ALK(p23,q21) fusion+
HuPS-03024T	Female	80	Adenocarcinoma	T2N2M0	IIB	2	EML4-ALK(p23,q21) fusion+
HuPS-03025T	Female	63	Adenocarcinoma	T2aN0M0	IB	3
HuPS-03026T	Female	67	Adenocarcinoma	T2bNoMo	IIA	3
HuPS-03027T	Male	65	Adenocarcinoma	T2aN0M0	IB	3
HuPS-03028T	Male	72	Adenocarcinoma	T3N0M0	IIB	3
HuPS-03029T	Male	68	Adenocarcinoma	T2N0Mo	IB	3
HuPS-03030T	Male	54	Adenocarcinoma	T2bN1M0	IIB	3
HuPS-03031T	Male	62	Squamous cell  carcinoma	T2bN0M0	IIA	2